Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)”

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01718379
What this trial is testing

Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.

Who this might be right for
Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 132
Testing effectiveness (Phase 2)Study completedNCT01048034
What this trial is testing

Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Who this might be right for
Myelodysplastic SyndromeChronic Myelomonocytic Leukemia
Nordic MDS Group 30
Early research (Phase 1)Study completedNCT00916227
What this trial is testing

ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndromes
Array Biopharma, now a wholly owned subsidiary of Pfizer 45
Testing effectiveness (Phase 2)Study completedNCT00910858
What this trial is testing

A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes

Who this might be right for
Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
Celgene Corporation 40
Large-scale testing (Phase 3)Active Not RecruitingNCT02598661
What this trial is testing

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndromes
Geron Corporation 289
Testing effectiveness (Phase 2)Study completedNCT03011034
What this trial is testing

Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Who this might be right for
Myelodysplastic Syndromes
Janssen Research & Development, LLC 34
Testing effectiveness (Phase 2)Ended earlyNCT00486720
What this trial is testing

Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)

Who this might be right for
Myelodysplastic SyndromesBlood DiseaseBone Marrow Disease
Merck Sharp & Dohme LLC 22
Testing effectiveness (Phase 2)Ended earlyNCT02240706
What this trial is testing

Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Boehringer Ingelheim 27
Testing effectiveness (Phase 2)Study completedNCT02335268
What this trial is testing

Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia

Who this might be right for
Myelodysplastic Syndromes
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH 77
Testing effectiveness (Phase 2)Study completedNCT03502668
What this trial is testing

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Who this might be right for
Myelodysplastic Syndromes
Taiho Oncology, Inc. 160
Testing effectiveness (Phase 2)Ended earlyNCT00467610
What this trial is testing

Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS

Who this might be right for
Myelodysplastic Syndrome
Rush University Medical Center 6
Testing effectiveness (Phase 2)Study completedNCT01338337
What this trial is testing

Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia

Who this might be right for
Myelodysplastic Syndrome (MDS)
Asociación Andaluza de Hematología y Hemoterapia 40
Testing effectiveness (Phase 2)Ended earlyNCT01422486
What this trial is testing

Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome (MDS)
Telik 2
Large-scale testing (Phase 3)Study completedNCT00179621
What this trial is testing

Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality

Who this might be right for
Myelodysplastic Syndromes
Celgene Corporation 205
Early research (Phase 1)Study completedNCT01895842
What this trial is testing

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 31
Early research (Phase 1)Study completedNCT01496495
What this trial is testing

ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Array Biopharma, now a wholly owned subsidiary of Pfizer 71
Not applicableStudy completedNCT02378701
What this trial is testing

Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 102
Testing effectiveness (Phase 2)Study completedNCT01497145
What this trial is testing

A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome

Who this might be right for
MDS
Kyowa Kirin Co., Ltd. 45
Testing effectiveness (Phase 2)Study completedNCT03337451
What this trial is testing

Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Opsona Therapeutics Ltd. 14
Testing effectiveness (Phase 2)Looking for participantsNCT03886662
What this trial is testing

LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic Syndromes
Lixte Biotechnology Holdings, Inc. 47
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation